On September 19, BioIntelliSense CCO Carolyn Walsh heads to EY’s Digital Health on the Hill to share how continuous patient monitoring is shaping the future of healthcare. It’s a future where wireless, multiparameter wearables like the medical-grade BioButton® device keep patients connected to care beyond the hospital walls into the comfort of home. BioIntelliSense will showcase this new standard of continuous care to industry leaders and lawmakers from around the country during the panel session ‘Screening for Success: ROI of Digital Health Interventions.’ Sushma Akunuru, SVP and Chief Information Officer at Independence Blue Cross, Robert E. Connely III, Global Industry Market Leader for Healthcare at Pega, and Randy Gaboriault MS, MBA, Chief Digital and Innovation Officer at ChristianaCare will also share their insights on digital health adoption during the session, which will be moderated by Jason Rife, Health Transformation at EY. #DigitalHealthontheHill #continuouscare #futureofhealthcare
BioIntelliSense, Inc
Medical Device
Denver, Colorado 7,958 followers
A New Era of Continuous Health Monitoring and Clinical Intelligence
About us
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Our medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The FDA-cleared, medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical-grade remote care from in-hospital to home. Learn how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services or visit our website at BioIntelliSense.com.
- Website
-
http://biointellisense.com
External link for BioIntelliSense, Inc
- Industry
- Medical Device
- Company size
- 51-200 employees
- Headquarters
- Denver, Colorado
- Type
- Privately Held
Locations
-
Primary
Denver, Colorado , US
Employees at BioIntelliSense, Inc
Updates
-
BioIntelliSense is advancing our understanding of human health here on Earth–and now in space as part of the Polaris Program's Polaris Dawn mission. The medical-grade BioButton® wearable device is currently being worn by the crew of Polaris Dawn during their historic 5-day mission. Researchers will use the physiologic data gathered before, during and after the mission to expand knowledge of what happens to the human body while in space. BioIntelliSense is proud to collaborate with the Translational Research Institute for Space Health (TRISH) to advance human health research on this groundbreaking mission. #futureofhealth #spacehealth
Liftoff!! 🚀 The Polaris Program’s Polaris Dawn has successfully launched! Congratulations to everyone involved in today's achievement, we are grateful for the opportunity to collaborate on such exciting research! The space health data collected from the Polaris Dawn crew will be stored in EXPAND and will contribute to our understanding of how spaceflight impacts human health. We’ll be closely monitoring the mission over the coming days and eagerly anticipate the crew's safe return! #SpaceHealth #TRISH (Photo: SpaceX)
-
Today, we’re excited to announce an exclusive license agreement with iRhythm Technologies, Inc. to use BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies within the ambulatory cardiac monitoring (ACM) market. Read more here: https://lnkd.in/g-wDcipg
-
At Houston Methodist, tech-enabled innovations are transforming patient care, improving efficiency and enhancing outcomes. Their approach to leveraging cutting-edge technologies, including the medical-grade BioButton™ wearable device, is a testament to the power of continuous monitoring and data-driven insights in improving healthcare delivery. It’s exciting to see such forward-thinking institutions embrace technologies that make a real difference in patient care. Read more about how Houston Methodist is redesigning healthcare and reimagining the patient experience: https://lnkd.in/gSE6Ejt7 #HealthcareInnovation #PatientCare #DigitalHealth
-
At BioIntelliSense, we’re helping to build the blueprint for the future of tech-enabled healthcare. Today, the FDA-cleared BioButton® wearable device is continuously monitoring over 100K patients, enabling clinicians to automate vital sign collection and to enable better, safer care from in-hospital to home. BioIntelliSense CEO James Mault, MD, FACS and CCO Carolyn Walsh recently contributed their industry expertise and key learnings to help shape the Consumer Technology Association’s newest #telehealth guidelines.
Today, the Consumer Technology Association published the 30th ( 🎉 ) #digitalhealth standard in our portfolio, CTA-2113 - Best Practices and Recommendations for Telehealth Solutions. This standard offers a comprehensive framework for integrating telehealth solutions into the healthcare system, for various use cases such as acute care, post-acute care, chronic care, and telehealth visits. CTA-2113 covers topics like simplicity, accuracy, privacy, cybersecurity, artificial intelligence, and data-driven decision making. It also helps overcome the barriers and challenges of implementing and scaling telehealth solutions, such as technological, regulatory, and organizational issues. Many thanks to the R11 WG 14 - Telehealth for the development of this important work and specifically James Mault, MD, FACS and Carolyn Walsh for their leadership! Download CTA-2113 here: https://lnkd.in/gAvcTgvk.
Best Practices and Recommendations for Telehealth Solutions (CTA-2113)
shop.cta.tech
-
Every minute counts – especially for nurses on the floor. At Houston Methodist, continuous vital sign monitoring with the BioButton® multiparameter wearable has helped nurses redirect 15 minutes per patient, per day, where they’re needed most. What this means: for a population of 250,000 patients, that adds up to 62,000 person-dedicated hours, or just over 7 years, that can be given back to patients who need hands-on care. Read more about the impact the BioButton is having at Houston Methodist in this recent issue of Roberta Schwartz’ “Healthcare Insights from Digital Innovation Obsessed People” LinkedIn newsletter ➡ https://lnkd.in/gfnWNkbT #patientmonitoring #medtech
The Rise of Remote Patient Monitoring Inside the Hospital
Roberta Schwartz on LinkedIn
-
Read the latest from mHealthIntelligence on the growing success of our system-wide inpatient program with all 8 Houston Methodist hospitals. The FDA-cleared BioButton® wearable and continuous monitoring solution is reducing clinical staff burden by automating vital sign collection for thousands of non-ICU patients each and every day. And we’re just getting started. Thanks for your coverage Anuja Vaidya. #RPM #healthtech #healthcareinnovation https://lnkd.in/euYM5SVE
How Houston Methodist is scaling inpatient RPM across its hospitals
mhealthintelligence.com
-
Take a tour of Houston Methodist’s state-of-the-art “virtual care command center” where med-surg patients are centrally monitored with the BioButton® multi-parameter wearable device and BioDashboard™ clinical intelligence solution. Sarah N Pletcher, MD MHCDS, Vice President and Executive Medical Director of Strategic Innovation at Houston Methodist, provides an inside view of the hospital system’s “Vitals Redesign” initiative leveraging the FDA-cleared BioButton device, which recently completed its expansion across all 2,653 non-ICU beds in all eight of the health system’s hospitals. https://lnkd.in/g_CAHpK5 #RPM #healthtech #healthcare
A Virtual Intensive Care Unit at Houston Methodist
https://www.youtube.com/
-
Leading hospitals & tens of thousands of patients are continuously monitored by the medical-grade BioButton from in-hospital to home. Listen to the latest about the clinical value we bring and the impact we make for providers and patients in this live interview with BioIntelliSense Founder and CEO, James Mault, MD, FACS as he talks with KMOX | Audacy news radio. Link: https://lnkd.in/g3X8ryBH #patientmonitoring #healthtech
BioButton allows patients and nurses to stay connected
omny.fm
-
We're thrilled to announce that James Mault, MD, FACS, Founder and CEO of BioIntelliSense, is joining the newly formed Advisory Board of M42 Health, alongside fellow health and technology luminaries David Rhew, M.D., Microsoft Global Chief Medical Officer and VP of Healthcare; David A. Sinclair A.O., Ph.D., Professor of Epigenetics and Longevity at Harvard University; and Sir Chris Evans, Chairman of Ellipses Pharma. The new M42 Advisory Board marks a critical milestone for the Abu Dhabi-based, global tech-enabled health and healthcare company with facilities in more than 26 countries. According to M42, the new Advisory Board will “drive M42’s vision to reshape the sustainable future of health through collaboration with other regional and international industry leaders. “The Advisory Board reflects M42’s commitment to bring together traditional health-tech and healthcare provisions under a holistic ‘health’ approach, focused on preventive, precise and personalized health solutions. This pioneering approach, coupled with M42’s cutting-edge innovation and commitment to reshaping the sustainable future of health, positions it as an unparalleled force in the global health sector.” Read more in today’s announcement: https://lnkd.in/gKRCV4EX #HealthcareInnovation #HealthTech #HealthcareFuture